Hopp til hovedinnhold

Allergivaksinering

Allergivaksinering, også kalt hyposensibilisering, kan brukes når du har en allergi som er vanskelig å kontrollere med medisiner. Tidligere ble vaksinen kun gitt som sprøyter, men nå brukes oftere smeltetabletter.

Sist revidert:

QR
Del pasientinformasjon

Den ligger åpent tilgjengelig på NHI.no sammen annen relevant informasjon

https://nhi.no/sykdommer/allergi/allergiforebygging/vaksinering-mot-allergi/ 

Hva er allergivaksinering?

Hvem kan ha nytte av allergivaksinering?

Behandlingsopplegget

Varighet

Bivirkninger

Tiltak for å hindre vaksinereaksjon

Fordelene med allergivaksinering

Vil du vite mer?

Kilder

Referanser

Dette dokumentet er basert på det profesjonelle dokumentet Allergivaksinasjon. Referanselisten for dette dokumentet vises nedenfor.

  1. Cox L. The role of allergen immunotherapy in the management of allergic rhinitis. Am J Rhinol Allergy 2016; 30: 48-53. pmid:26867530 PubMed 
  2. Huggins JL, Looney RJ. Allergen immunotherapy. Am Fam Physician 2004; 70: 689-96. PubMed 
  3. Hansen TK, Svendsen UG. Allergenspecifik immunterapi. Ugeskr Læger 2005; 167: 666-71. PubMed 
  4. Øymar K. Allergivaksinasjon i Norge. Tidsskr Nor Lægeforen 2007; 127: 1036-8. PubMed 
  5. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Geneva: January 27-29, 1997. Allergy 1998; 53(44 suppl): 1-42.
  6. Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database of Systematic Reviews 2010, Issue 12. Art. No.: CD002893. DOI: 10.1002/14651858.CD002893.pub2 DOI 
  7. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD001936. DOI: 10.1002/14651858.CD001936.pub2. DOI 
  8. What are the benefits and harms of sublingual immunotherapy compared with placebo in people with allergic rhinitis? Elie Mulhem (MD) (on behalf of Cochrane Clinical Answers Editors). Cochrane Clinical Answers 2014. DOI: 10.1002/cca.237.
  9. Rak S, Yang WH, Pedersen MR, Durham SR. Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: a double-blind, randomised study. Qual Life Res 2007; 16: 191-201. PubMed 
  10. Barr JG, Al-Reefy H, Fox AT, et al. Allergic rhinitis in children. BMJ. 2014 ;349:g4153. doi: 10.1136/bmj.g4153 DOI 
  11. Calderon MA, Penagos M, Sheikh A, et.al. Sublingual immunotherapy for treating allergic conjunctivitis. Cochrane Database of Systematic Reviews 2011, Issue 7. Art. No.: CD007685. DOI: 10.1002/14651858.CD007685.pub2. DOI 
  12. Golden DBK, Kagey-Sobotka A, Norman PS, Hamilton RG, Lichtenstein LM. Outcomes of allergy to insect stings in children, with and without venom immunotherapy. N Engl J Med 2004; 351: 668-74. New England Journal of Medicine 
  13. Boyle RJ, Elremeli M, Hockenhull J, Cherry MG, Bulsara MK, Daniels M, Oude Elberink J. Venom immunotherapy for preventing allergic reactions to insect stings. Cochrane Database of Systematic Reviews 2012, Issue 10. Art. No.: CD008838. DOI: 10.1002/14651858.CD008838.pub2. DOI 
  14. Normansell R, Kew KM, Bridgman AL. Sublingual immunotherapy for asthma. Cochrane Database of Systematic Reviews 2015, Issue 8. Art. No.: CD011293. DOI: 10.1002/14651858.CD011293.pub2. DOI 
  15. Romantsik O, Tosca MA, Zappettini S, Calevo MG. Oral and sublingual immunotherapy for egg allergy. Cochrane Database of Systematic Reviews 2018, Issue 4. Art. No.: CD010638. DOI: 10.1002/14651858.CD010638.pub3. DOI 
  16. Tam H, Calderon MA, Manikam L, Nankervis H, García Núñez I, Williams HC, Durham S, Boyle RJ. Specific allergen immunotherapy for the treatment of atopic eczema. Cochrane Database of Systematic Reviews 2016, Issue 2. Art. No.: CD008774. DOI: 10.1002/14651858.CD008774.pub2. DOI 
  17. Lockey RF, Nicoara-Kasti GL, Theodoropoulos DS, Bukantz SC. Systemic reactions and fatalities associated with allergen immunotherapy. Ann Allergy Asthma Immunol 2001; 87(1 suppl 1): 47-55.
  18. Steinsvåg SK, Florvaag E. Allergivaksinasjon - hvorfor og hvordan. Tidsskr Nor Lægeforen 2005; 125: 1489-90. PubMed 
  19. Bolle R, Berstad A, Florvaag E, Steinsvåg S. Praktisk veileder i allergivaksinasjon. Norsk Forening for Allergologi og Immunpatologi. Utgave2, 2011. legeforeningen.no 
  20. Dhami S, Nurmatov U, Arasi S, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta-analysis. Allergy. 2017;72(11):1597-1631. Pmid: 28493631 PubMed 
  21. Elliott J, Kelly SE, Johnston A, Skidmore B, Gomes T, Wells GA. Allergen immunotherapy for the treatment of allergic rhinitis and/or asthma: an umbrella review. CMAJ Open. 2017 May 10;5(2):E373-E385. PMID: 28495938 PubMed 
  22. Moller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jacobsen L, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109: 251-6. PubMed 
  23. Grembiale RD, Camporota L, Naty S, Tranfa CM, Djukanovic R, Marsico SA. Effects of specific immunotherapy in allergic rhinitic individuals with bronchial hyperresponsiveness. Am J Respir Crit Care Med 2000; 162: 2048-52. PubMed 
  24. Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341: 468-75. New England Journal of Medicine 
  25. Jacobsen L, Nüchel Petersen B, Wihl JA et al. Immunotherapy with partially purified and standardized tree pollen extracts. IV. Results from long-term (6-year) follow-up. Allergy 1997; 52: 914-20. PubMed 
  26. Frølund L, Durham SR, Calderon M, et al. Sustained effect of SQ-standardized grass allergy immunotherapy tablet on rhinoconjunctivitis quality of life. Allergy 2009; : PMID: 17033900. PubMed 
  27. Di Bona D, Plaia A, Leto-Barone MS, et al. Efficacy of grass pollen allergen sublingual immunotherapy tablets for seasonal allergic rhinoconjunctivitis: A systematic review and meta-analysis. JAMA Intern Med. 2015. doi: 10.1001/jamainternmed.2015.2840.